- Human pathology

Home > G. Tumoral pathology > Molecular pathology of tumors > Genetic anomalies > Amplifications > Gene amplications > MYC amplification

MYC amplification

HGNC:7553 8q24 MIM:190080

Monday 8 August 2016


- Amplification of MYC and nuclear expression of MYC is present in secondary angiosarcoma but not atypical vascular lesion (AVL). (22121953)

  • Secondary angiosarcoma and benign but microscopically atypical vascular proliferations (herein referred to as atypical vascular lesion or AVL) are rare consequences of radiation therapy and/or chronic lymphedema most commonly seen in breast cancer patients.
  • Differentiating angiosarcoma from AVL can be difficult due to overlapping clinical and microscopic features.
  • Amplification of MYC has been associated with 55-100% of secondary angiosarcomas but is reportedly absent in AVL.

- Atypical vascular lesions (AVLs) and angiosarcomas (ASs) are well-recognized complications of radiotherapy for breast cancer.

  • Early diagnosis may be challenging, particularly on small biopsies, and the treatment options are limited.
  • MYC and sometimes FLT4 gene amplification has been reported in AS, but not in AVL, and FLT4 may be a target for therapy. (25864386)

Paywall references

- Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. Ginter PS, Mosquera JM, MacDonald TY, D’Alfonso TM, Rubin MA, Shin SJ. Hum Pathol. 2014 Apr;45(4):709-16. doi : 10.1016/j.humpath.2013.11.002
PMID: 24457083